Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Optibrium Ltd
Optibrium Ltd
Activities:
Research & Development
Digital
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Optibrium launches a metabolism prediction software platform tailored to DMPK scientists
Semeta can be used for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery
Finance
Optibrium acquires 3D drug design specialist BioPharmics
Following the acquisition, BioPharmics’ Drs Ajay Jain (CEO) and Ann Cleves (Director of Applied Science) join the Optibrium team as VP in the newly-created BioPharmics Division
Finance
Optibrium receives further investment from Kester Capital
Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology
Finance
Optibrium appoints Prof Andy Black non-executive chair
Prior to his current roles, Black co-founded Kinapse, an international business providing expert advisory and implementation services to life science industries
Research & Development
Optibrium releases 3D design module for drug discovery software
This expansion is a result of a collaboration between BioPharmics and Optibrium
Finance
Optibrium and BioPharmics enter computational drug design collaboration
The Surflex eSim 3D module, planned for the 3rd quarter of 2021, will use BioPharmics’ 3D ligand-based design approaches
Drug Delivery
Optibrium launches AI software platform for drug discovery
It's the latest member of Optibrium's Augmented Chemistry platform of AI technologies
Subscribe now